Full Text
Cost-Effectiveness of Escalating to Natalizumab or Switching Among Immunomodulators In Relapsing-Remitting Multiple Sclerosis In Italy

Abstract

Authors

G Furneri L Santoni C Ricella L Prosperini

Back to Volume 18, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×